Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD25 monoclonal antibody BA1106

A human monoclonal antibody directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra), with potential antineoplastic activity. Upon administration, anti-CD25 monoclonal antibody BA1106 targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells in the tumor microenvironment (TME) through antibody-dependent cellular cytotoxicity (ADCC) and prevent immunosuppression, thereby increasing the number of effector T (Teff) cells and enhancing anti-tumor immune responses. CD25, the alpha chain of the IL-2 receptor, is highly expressed on Treg cells but not on Teff cells in tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BA 1106
BA-1106
BA1106
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search